On June 2, 2021 Onco360, the nation’s largest independent Oncology Pharmacy, reported that it has been selected by Takeda to be a specialty pharmacy partner for ALUNBRIG (brigatinib), an oral therapy option for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) (Press release, Onco360, JUN 2, 2021, View Source;positive-Metastatic-Non-Small-Cell-Lung-Cancer-NSCLC [SID1234583419]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Onco360 is excited to become a specialty pharmacy provider for ALUNBRIG patients," said Benito Fernandez, Chief Commercial Officer, Onco360. "As a provider of this important treatment option for patients, Onco360 is committed to supporting the highly specialized needs of ALK-positive metastatic NSCLC patients and their physicians across the United States."

According to the National Cancer Institute’s (NCI) Surveillance, Epidemiology, and End Results (SEER) Program, approximately 235,760 patients will be diagnosed with lung cancer in 2021 with a corresponding 131,880 deaths. Approximately 85% of lung cancer cases are represented by NSCLC. When considering all subtypes of lung cancer as well as stages of the disease, lung cancer patients have a poor five-year overall survival (OS) of 21.7%. Unfortunately, 56% of lung cancer patients will have incurable, metastatic disease at the time of initial diagnosis.1 Approximately 4-to-5% of NSCLC patients have genetic mutations which can be classified as ALK-positive.2

ALUNBRIG is manufactured by Takeda, a commercial-stage biotechnology company. The FDA’s approval of ALUNBRIG is based upon the results of multiple clinical trials including the Phase III ALTA 1L (NCT02737501) clinical trial which demonstrated that ALUNBRIG administration resulted in a 51% improvement in progression-free survival (PFS) compared to XALKORI in treatment-naïve patients with ALK-positive metastatic NSCLC patients.3 For full prescribing information, visit ALUNBRIG.com.